Immunocore – New Biomarker Research Builds Further Understanding of Tebentafusp (IMCgp100) Mechanism of Action, Link to Clinical Activity in Advanced Melanoma

(Oxfordshire, UK and Conshohocken, Pennsylvania and Rockville, Maryland, US, 3 June 2019) Monotherapy treatment with the first-in-class ImmTAC® molecule tebentafusp (IMCgp100) induced an immunologically potent response in patients with advanced uveal and cutaneous melanoma, according to new data presented today by Immunocore Limited at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The biomarker research provides additional insight into the mechanism of action of tebentafusp in patients with advanced melanoma and demonstrates the potential association with clinical outcomes.